Pieris Pharmaceuticals (PIRS) Short Interest Ratio & Short Volume

Short interest is the volume of Pieris Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 10,300 shares of PIRS short. 0.84% of Pieris Pharmaceuticals' shares are currently sold short. Learn More on Pieris Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.84% of Pieris Pharmaceuticals' floating shares are currently sold short.

Pieris Pharmaceuticals saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 10,300 shares, a decline of 42.5% from the previous total of 17,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Pieris Pharmaceuticals currently has issued a total of 1,320,000 shares. Some of Pieris Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Pieris Pharmaceuticals currently has a public float of 1,230,000 shares.

0.84% of Pieris Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Pieris Pharmaceuticals: Cue Biopharma, Inc. (7.65%), Xilio Therapeutics, Inc. (0.70%), Aadi Bioscience, Inc. (1.33%), Immuneering Co. (13.71%), VYNE Therapeutics Inc. (0.50%), Equillium, Inc. (1.20%), Lipocine Inc. (2.29%), Daré Bioscience, Inc. (0.71%), Lisata Therapeutics, Inc. (0.16%), Reviva Pharmaceuticals Holdings, Inc. (12.97%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.13 billion), Royal Caribbean Cruises Ltd. ($2.77 billion), Moderna, Inc. ($2.76 billion), Coinbase Global, Inc. ($2.36 billion), Rivian Automotive, Inc. ($2.22 billion), Paychex, Inc. ($2.02 billion), Tractor Supply ($1.81 billion), Enphase Energy, Inc. ($1.65 billion), Chesapeake Energy Co. ($1.62 billion), and Lululemon Athletica Inc. ($1.58 billion). View all of the most shorted stocks.

Short selling PIRS is an investing strategy that aims to generate trading profit from Pieris Pharmaceuticals as its price is falling. PIRS shares are trading down $0.30 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Pieris Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PIRS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PIRS, twice per month. The most recent reporting period available is July, 15 2024.